Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Kidney Int. 2022 Feb;101(2):414-415. doi: 10.1016/j.kint.2021.11.012. Epub 2021 Nov 22.

Authors

Sam Kant¹, Antoine Azar², Duvuru Geetha³

Affiliations

¹ Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
² Division of Allergy and Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: gduvura@jhmi.edu.

No abstract available

Publication types

Letter

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Antineutrophil Cytoplasmic
Antibody Formation
COVID-19 Vaccines
COVID-19*
Humans
Remission Induction
Rituximab / adverse effects
SARS-CoV-2

Substances

Antibodies, Antineutrophil Cytoplasmic
COVID-19 Vaccines
Rituximab